NCT01418092View on ClinicalTrials.gov

ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
OIC
Interventions
DRUG

ALKS 37

Capsules for oral administration

DRUG

Placebo

Capsules for oral administration

Trial Locations (13)

19139

Alkermes Investigational Site, Philadelphia

27612

Alkermes Investigational Site, Raleigh

30060

Alkermes Investigational Site, Marietta

32117

Alkermes Investigational Site, Daytona Beach

33317

Alkermes Investigational Site, Plantation

46250

Alkermes Investigational Site, Indianapolis

77098

Alkermes Investigational Site, Houston

78756

Alkermes Investigational Site, Austin

89119

Alkermes Investigational Site, Las Vegas

92804

Alkermes Investigational Site, Anaheim

92868

Alkermes Investigational Site, Orange

98007

Alkermes Investigational Site, Bellevue

08046

Alkermes Investigational Site, Willingboro

Sponsors

Lead Sponsor

Alkermes, Inc.
All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY

NCT01418092 - ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC) | Biotech Hunter | Biotech Hunter